Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: SELL (auto-tracking)
2.81% $7.68
America/New_York / 23 apr 2024 @ 15:16
FUNDAMENTALS | |
---|---|
MarketCap: | 544.48 mill |
EPS: | -1.660 |
P/E: | -4.63 |
Earnings Date: | May 09, 2024 |
SharesOutstanding: | 70.90 mill |
Avg Daily Volume: | 4.76 mill |
RATING 2024-04-23 |
---|
B- |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Sell | |
P/E: | Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -4.63 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.79x |
Company: PE -4.63 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$2.52 (-67.24%) $-5.16 |
Date: 2024-04-23 |
Expected Trading Range (DAY) |
---|
$ 6.70 - 8.74 ( +/- 13.19%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-02 | Roberts M Scot | Buy | 7 775 | Common Stock, par value $0.0001 |
2024-02-02 | Roberts M Scot | Sell | 2 330 | Common Stock, par value $0.0001 |
2024-02-01 | Roberts M Scot | Buy | 6 166 | Common Stock, par value $0.0001 |
2024-02-01 | Roberts M Scot | Sell | 1 801 | Common Stock, par value $0.0001 |
2024-02-02 | Roberts M Scot | Sell | 7 775 | Restricted Stock Units |
INSIDER POWER |
---|
81.82 |
Last 99 transactions |
Buy: 2 849 671 | Sell: 279 919 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $7.68 (2.81% ) |
Volume | 2.39 mill |
Avg. Vol. | 4.76 mill |
% of Avg. Vol | 50.31 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $9.63 | N/A | Active |
---|
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.